Benzinga | Apr 8, 2021 08:02AM EDT

GT Biopharma Announces Enrollment Of Patient 10 In GTB-3550 TriKE Phase I/II Clinical Trial

GT Biopharma, Inc. (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary NK cell engager (TriKE(tm)) protein biologic technology platform, is pleased to announce the enrollment of Patient 10 in its GTB-3550 TriKE(tm) first-in-human Phase I/II clinical trial for the treatment of high-risk myelodysplastic syndromes (MDS) and refractory/relapsed acute myeloid leukemia (AML). Patient 10 will be dosed at 100mcg/kg/day.